WHAT:Staphylococcus epidermidis bacteria are a significant health concern for hospitalized infants, children and anyone with implanted medical devices. The bacteria -- typically skin dwellers -- can infect the bloodstream and cause a life-threatening condition known as sepsis. Between 1 and 3 million people a year in the United States are diagnosed with sepsis, and between 15 and 30 percent of them die. Severe bacterial sepsis is characterized by an extreme immune response, inflammation, reduced blood flow, clotting, and organ failure. Methicillin-resistant strains of S. epidermidis (MRSE) cause most sepsis cases. Notably, methicillin resistance rates in S. epidermidis exceed those in the more-familiar S. aureus (MRSA), and methicillin resistance makes MRSE infections difficult to treat.
For decades scientists have thought that S. epidermidis sepsis resulted from an overwhelming immune response to unchanging surface structures on the invading bacteria. Now, National Institutes of Health (NIH) scientists have identified an S. epidermidis toxin (PSM-mec) that is released into the bloodstream and contributes to sepsis. The investigators say this is the first time a toxin from S. epidermidis or closely related bacteria has been linked to sepsis.
In tissue studies using S. epidermidis strains, the group found that the PSM-mec toxin helped the bacteria survive in human blood and resist attack by neutrophils, important immune system fighters. In a mouse model, the toxin significantly increased disease and stimulated the immune response, which worsened the septic infection.
The researchers say clinical studies are needed to assess whether PSM-mec affects sepsis in people and thus can be a target for therapeutics. They also are investigating whether related toxins found in methicillin-susceptible S. epidermidis and S. aureus have a similar function.
Scientists from NIH's National Institute of Allergy and Infectious Diseases led the project.
L Qin et al. Toxin mediates sepsis caused by methicillin-resistant Staphylococcus epidermidis. PLoS Pathogens DOI: 10.1371/journal.ppat.1006153 (2017).
Michael Otto, Ph.D., a senior investigator in NIAID's Laboratory of Bacteriology, is available for comment. Dr. Otto is an expert in the molecular basis of pathogenesis in staphylococci.
To schedule interviews, please contact Ken Pekoc, 301-402-1663, email@example.com.
NIAID conducts and supports research -- at NIH, throughout the United States, and worldwide -- to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.
NIH...Turning Discovery Into Health®